title: Use of a nonionic detergent (Triton WR 1339) in healthy cats to assess hepatic secretion of triglyceride.
abstract: OBJECTIVE
  To determine whether a nonionic detergent (Triton WR 1339) can be used in cats to assess hepatic secretion of triglyceride.
  
  
  METHODS
  28 healthy cats.
  
  
  METHODS
  Triton WR 1339 was administered IV according to the following schedule: 5, 50, 150, and 250 mg/kg of body weight. Control cats did not receive an injection or received 0.9% NaCl or PBS solutions at the same osmolarity and volume as the 250 mg/kg group. Blood samples were collected throughout the 48-hour period after administration for determination of triglyceride and cholesterol concentrations and for RBC morphology and osmotic fragility studies.
  
  
  RESULTS
  Administration of Triton WR 1339 at 150 and 250 mg/kg caused profound hypertriglyceridemia. Triglyceride concentrations increased in a curvilinear fashion for the first 2 hours and remained increased for approximately 24 hours. Area under the time-concentration curve for triglyceride at 5 hours differed significantly among groups. At 12 and 24 hours, cholesterol was significantly higher in cats receiving 250 mg/kg. The most dramatic changes in osmotic fragility and RBC morphology were in cats receiving 250 mg/kg; 1 of these cats developed severe icterus and died 5 days later. Feeding rice and casein before administering Triton WR 1339 at 150 mg/kg did not appear to affect the hypertriglyceridemia response.
  
  
  CONCLUSIONS
  Triton WR 1339 can be administered IV to cats at a rate of 150 mg/kg to assess hepatic triglyceride secretion, although some cats may have increased RBC osmotic fragility. Higher dosages caused substantial adverse effects, whereas lower dosages did not alter plasma triglyceride concentration.
authors.affiliation: Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis 97331-4802, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Hall
authors.forename: J L
authors.initials: JL
authors.lastname: Gradin
authors.forename: C B
authors.initials: CB
authors.lastname: Andreasen
authors.forename: R C
authors.initials: RC
authors.lastname: Wander
mesh_terms: D000818:Animals; D019540:Area Under Curve; D002364:Caseins / Q000008:administration & dosage / Q000378:metabolism; D002415:Cats / Q000502:physiology*; D002784:Cholesterol / Q000097:blood / Q000378:metabolism*; D004906:Erythrocyte Count / Q000662:veterinary; D005260:Female; D008099:Liver / Q000378:metabolism*; D008297:Male; D012275:Oryza / Q000378:metabolism; D009996:Osmotic Fragility / Q000187:drug effects; D011092:Polyethylene Glycols; D013501:Surface-Active Agents; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
chemical_list: D002364:Caseins; D013501:Surface-Active Agents; D014280:Triglycerides; D011092:Polyethylene Glycols; D002784:Cholesterol; C016811:tyloxapol